The purpose of this study was to determine whether smoking cessation improves flow-mediated dilation (FMD) of the brachial artery.
brachial artery (BA) is a noninvasive, validated measure that quantifies endothelial function and predicts future CVD events (13, 14) . In clinical and epidemiological studies, smokinginduced endothelial dysfunction seems to be dose related and may be reversible after smoking cessation (11, 12, 15) . However, the mechanisms by which smoking cessation reduces CVD risk are unclear, and the long-term effects of continued smoking and smoking cessation on endothelial function have not been established. This study evaluated the effects of current smoking and smoking cessation on endothelial function in a prospective, randomized clinical trial of smoking cessation pharmacotherapy (16) . We hypothesized that smoking cessation would improve endothelial function of the BA.
Methods
Study participants and design. The institutional review board at the University of Wisconsin School of Medicine and Public Health approved this study. All subjects provided written informed consent. This was a 3-year longitudinal, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of 5 smoking cessation pharmacotherapies and to examine the natural history of continued smoking and smoking cessation on subclinical atherosclerosis (16) . This article describes the independent predictors of BA FMD in current smokers at baseline, before smoking cessation treatment, and 1 year after the target quit date.
Participants were randomized to 1 of 6 treatment conditions: nicotine lozenge, nicotine patch, sustained-release bupropion, nicotine patch plus nicotine lozenge, sustainedrelease bupropion plus nicotine lozenge, or placebo (Online Appendix 1) (16) . All participants received individual counseling sessions (16) . Major inclusion criteria were age 18 years and older, smoking Ն10 cigarettes/day, expired carbon monoxide (CO) level Ͼ9 ppm, and stated motivation to quit smoking. Major exclusion criteria were blood pressure (BP) Ͼ160/100 mm Hg, myocardial infarction within the previous 4 weeks, heavy alcohol use, history of seizure or serious head injury, use of contraindicated medications, and current pregnancy or breastfeeding (16) . Study procedures. Subjects were recruited from communities in and around Madison and Milwaukee, Wisconsin, from January 2005 to June 2007. The baseline clinical trial visit included measurement of anthropometric data, fasting laboratory tests, and completion of validated questionnaires and interviews. Physical activity was assessed by the International Physical Activity Questionnaire (17) . Smoking burden was evaluated by current cigarette smoking (cigarettes/day) and pack-years (current cigarettes per day ϫ years smoked). Recent smoke exposure was measured by an exhaled CO level, which reflects smoking efficiency and recent smoke exposure. Smoking status was assessed by self-reported 7-day point-prevalence abstinence and was confirmed by an expired CO level of Ͻ10 ppm. Cotinine was not used to assess abstinence because interventions in this study included nicotine replacement therapy, which could have produced false-positive results. When used with self-report to indicate whether a person has smoked, CO and cotinine levels show high agreement (18) . Three selfreported measures of environmental smoke exposure were evaluated at baseline: whether smoking was allowed inside the home (home smoking ban), whether the subject lives with a partner/spouse who smokes, and whether smoking was allowed in the workplace. There is a strong relationship between self-reports of home and work smoke exposure and cotinine levels (19) . Fasting blood samples were obtained by venipuncture and were refrigerated. Plasma aliquots were isolated by centrifugation and frozen at Ϫ70°C. Measurement of BA reactivity. Endothelial function was evaluated by measuring the FMD of the BA in a core ultrasound laboratory using a standardized protocol (13, 20) . BA reactivity studies were performed at baseline, before initiating therapy, and 1 year after the target quit date. Subjects were required to be fasting and not use any tobacco-containing products for 8 h before the study. Subjects were placed in a supine position in a temperaturecontrolled room for 10 min before imaging. A BP cuff was placed on the widest part of the proximal right forearm. Using a 10-MHz linear array vascular ultrasound transducer and a Siemens Medical Solutions (Issaquah, Washington) CV70 ultrasound system, the BA was located above the elbow and scanned in longitudinal sections. Extravascular landmarks were identified and labeled to ensure reproducibility within and between studies. After recording baseline B-mode ultrasound images of the BA and spectral Doppler ultrasound images of flow, the cuff was inflated to 250 mm Hg for 5 min to induce reactive hyperemia (RH). Immediately after deflation, spectral Doppler ultrasound images were obtained to verify hyperemia. BA images were obtained 60 and 90 s later. Studies were recorded digitally; BA diameters were measured in triplicate with a digital border tracing tool (Access Point Web 3.0, Freeland Systems, Westfield, Indiana) by 3 readers blinded to subject information and treatment. The same reader read the baseline and follow-up studies in all subjects. The primary outcome variable was the maximum FMD (in %), the largest percentage of change in the BA diameter after RH relative to the baseline diameter. The absolute maximum FMD (in cm), the absolute difference in BA size after RH compared with baseline, also was reported.
All sonographers completed a standardized certification program. Ultrasound equipment was monitored using a small-parts phantom. In our laboratory, subjects who un- Because sex was strongly correlated with baseline diameter, separate analyses were performed for men and women. The mean difference in the BA diameter (in cm) and the absolute ⌬FMD (in %) from baseline to 1 year after the target quit date were analyzed. t tests were used to evaluate differences between subjects who did and did not return for the 1-year FMD visit. Next, we conducted a series of univariate analyses of variance to test for differences among the treatment conditions on 2 dependent variables: changes in baseline diameter and maximum FMD from baseline to year 1. Because treatment condition was not significantly related to the dependent variables, it was not covaried in later analyses. The t tests were used to evaluate differences in ⌬FMD and ⌬BA diameter by sex and within and between groups who quit smoking versus those who continued smoking. Multivariate regression analyses were used to determine variables that independently predicted ⌬FMD at 1 year after the target quit date. All models were adjusted for ⌬BA diameter and reader. Baseline variables and changes in variables from baseline to year 1 were considered in the ⌬FMD analysis.
All variables were examined with regard to their distributional properties by visual inspection and assessment of kurtosis and skew. Four variables were not normally distributed: pack-years, triglycerides, high-sensitivity C-reactive protein (hsCRP), and baseline BA flow. These values were log-transformed and comparisons were repeated, but comparable results were seen. Log-transformed values of these variables were retested in the multivariate models, and no major changes were observed. Residual plots from all reported regression models were inspected and seemed to be normally distributed.
Results
Subject characteristics. Subject characteristics at baseline and after 1-year follow-up are shown in Table 1 . Baseline studies were performed in 1,504 current smokers before Subject Characteristics at Baseline and 1 Year After the Target Quit Date Because BA diameter was consistently associated with FMD and has been shown to predict CVD events as well as FMD (14, 21) , associations with BA diameter were identified. Significant (p Ͻ 0.005) correlations for BA were seen with body mass index (r ϭ 0.24), waist circumference (r ϭ 0.42), systolic BP, diastolic BP, age, cigarettes smoked per day, pack-years, creatinine, glucose, hematocrit, HDL-C, triglycerides, physical activity, and C-reactive protein (p ϭ 0.029). BA diameter (Table 5) Among subjects who quit smoking, FMD increased from 6.2% (SD ϭ 4.4%) to 7.2% (SD ϭ 4.2%) after 1 year (p ϭ 0.005) (Fig. 1) . Among subjects who continued smoking, the change in FMD from 6.5% (SD ϭ 4.3%) to 6.6% (SD ϭ 4.1%) was not significant (p ϭ 0.643). BA diameter, BA flow, and RH flow did not change among or between abstainers and continuing smokers. Independent predictors of change in FMD after 1 year were abstinence from cigarette smoking (p ϭ 0.010), ⌬BA diameter (p Ͻ 0.001), ⌬RH flow (p Ͻ 0.001), ⌬LDL-C (p ϭ 0.004), and a home smoking ban (p ϭ 0.04) (R 2 adj ϭ 0.284) ( Table 6 ). Regarding environmental smoke exposure, only the presence of a home smoking ban predicted ⌬FMD. Adding the presence of a home smoking ban to the multivariate model attenuated the effect of abstinence on ⌬FMD slightly (Online Appendix 3); however, there was no significant interaction between a home smoking ban and smoking cessation (p ϭ 0.304). Baseline smoking burden (cigarettes/ day) did not affect the change in FMD after cessation; ⌬FMD did not differ between quartiles of cigarettes per day, and baseline cigarettes per day was not an independent predictor of ⌬FMD (p ϭ 0.304) (Online Appendix 4). Other than the home smoking ban, none of the baseline variables, including age and sex, predicted ⌬FMD after 1 year. Multivariate models showed no significant associations between ⌬FMD and changes in the following variables: C-reactive protein, body mass index, waist circumference, glucose, and HDL-C. BA diameter was a strong predictor of FMD in all models; models of ⌬FMD without ⌬BA diameter had a much lower R 2 adj (0.040).
Discussion
This was the largest prospective, randomized clinical trial to date that evaluated the effects of smoking cessation and continued smoking on endothelial function. Individuals who stopped smoking experienced a significant improvement in endothelial function, despite gaining weight. The cross-sectional and longitudinal components of this study 
highlight important pathophysiological relationships among cigarette smoking, arterial dysfunction, and risk factors for CVD among current smokers and individuals who quit smoking. The improvement in FMD 1 year after smoking cessation that we identified is consistent with that of a previous report from a smaller, observational cohort study (11) . The relationship between abstinence and improved FMD that we identified remained significant even after adjusting for changes in BA diameter and RH blood flow. Although BA diameter and BP did not significantly change with abstinence, heart rate was numerically lower in abstainers compared with continuing smokers, so it is possible that smoking affected vasomotor tone.
A sentinel finding in our study is that FMD improved among abstainers, despite weight gain. Abstainers gained significantly more weight and had larger waist circumferences after 1 year than did continuing smokers, consistent with previous findings (22) . Although increases in central adiposity are associated with adverse CVD risk factors and endothelial dysfunction, in regard to FMD, the salutary effects of smoking cessation seemed to outweigh the adverse effects of weight gain. However, weight gain may explain the absence of a significant difference in hsCRP between abstainers and continuing smokers.
The 1% absolute increase in FMD among smokers is not as dramatic as that reported with statins and other interventions (13); however, it is well within the measurement variability of our laboratory (20) . In contrast to most statin studies of FMD, our study population was heterogeneous and included individuals with a higher risk factor burden (smoking, overweight, low HDL-C), some of which improved (smoking, HDL-C) and some of which worsened (overweight) over time. Also, our treatment effect may be underestimated because subjects who quit smoking may still be exposed to environmental cigarette smoke. An approximate 1% difference in FMD is associated with a significantly lower rate of incident CVD events (14) . Extended follow-up would be necessary to evaluate the relationship between FMD changes 1 year after smoking cessation and future CVD events.
The presence of a home smoking ban was associated with greater improvement in FMD; however, it did not significantly interact with the effect of abstinence on FMD. Therefore, environmental restrictions on smoke exposure and an individual's successful smoking cessation both contribute to improvement in FMD. Further research should include biochemical measures of environmental smoke exposure. Reductions in LDL-C also predicted improvement in FMD. Elevated LDL-C is a risk factor for CVD, and changes in LDL-C are associated with changes in FMD (21) . Although smoking status did not influence LDL-C, LDL-C can change over time due to diet, aging, and medication use. Because of our large sample size, we were able to detect changes in FMD related to changes in LDL-C over 1 year. Importantly, baseline markers of smoking intensity and baseline CVD risk factors did not predict changes in FMD after 1 year, suggesting that changes in behaviors associated with smoking and LDL-C influence CVD risk. Mechanistically, endothelial nitric oxide synthase seems to promote release of endothelial progenitor cells from the bone marrow (23) . Improved FMD of the BA, as seen in our study, is nitric oxide Table 6 Predictors of Change in FMD (%), dependent (9, 14) . It is likely that smoking cessation reduces oxidative damage to endothelial cells, increases nitric oxide availability, and increases mobilization of endothelial progenitor cells from the bone marrow, indicating arterial repair and reduction in CVD risk (4, 9, 10) . Endothelial dysfunction is one of several mechanisms by which cigarette smoking promotes atherosclerosis (4, 5, 8, 9, 11, 12) . In our cross-sectional analysis of Ͼ1,500 individuals who smoked at least 10 cigarettes/day, HDL-C and CO levels significantly predicted FMD, an established measure of endothelial function that predicts future CVD events (9, 13, 14) ; however, BA diameter was the most powerful predictor of FMD, accounting for most of the variance in FMD in current smokers. Independent predictors of baseline BA diameter included age, male sex, waist circumference, glucose, and physical activity. These findings are consistent with those of previous reports showing that BA diameter is strongly associated with CVD risk factors and predicts CVD events (14, 21) . Although BA diameter is the strongest predictor of FMD in smokers, BA diameter seems to reflect the influence of additional CVD risk factors that contribute to endothelial dysfunction and atherogenesis.
We found strong positive correlations among BA diameter, waist circumference, and body mass index, as well as larger BA diameters among men compared with women. FMD in male smokers was predicted by BA diameter and triglycerides, a component of metabolic syndrome. In women, FMD was predicted by BA diameter and low HDL-C, which also is a component of metabolic syndrome and a predictor of CVD. To determine whether BA diameter was masking other significant predictors of FMD, we created separate models without BA diameter and found the expected directional relationships among FMD, age, sex, and CO; however, no other CVD risk factors were independently associated with FMD. These models accounted for less variance than did those that included BA diameter. The confounding relationship between BA size and body size in studies of FMD has been described previously (24, 25) . Patients with metabolic syndrome have larger BA diameters than those without (25) . The inverse relationship between HDL-C and baseline FMD that we observed in our multivariate models most likely was due to intercorrelations between HDL-C, body size (waist circumference, male sex), and BA diameter.
In regard to smoking parameters, CO, a measure of smoking heaviness, was independently associated with baseline FMD, but measures of smoking quantity such as cigarettes per day and pack-years were not. Previous reports had conflicting conclusions about a dose-response relationship between cigarette smoking and CVD risk (4, 5) . Our study suggests that an objective measure of smoking intensity (e.g., CO) is more likely to yield evidence of a dose-response relationship than are self-reported smoking rates (4, 5) . This is consistent with evidence that smokers tend to titrate their intake of nicotine by how intensively and efficiently they smoke each cigarette, which is reflected by CO levels, as opposed to the number of cigarettes that they smoke each day (26) . Study limitations. This was a randomized clinical trial of smoking cessation interventions, and thus there were no nonsmoking controls; therefore, we cannot determine the extent to which FMD approached normal values. The stability of FMD among those who continued to smoke, the similar FMD findings in each study arm, and the documented reproducibility of FMD techniques in our laboratory suggest that our findings are not due to chance and would not be seen in nonsmokers (20) . Because FMD was only measured at baseline and after 1 year, we could not evaluate the time course of FMD improvement with quitting.
In smoking cessation studies, it is common for subjects who relapse to drop out or miss follow-up visits (27) (28) (29) . In our study, 38.6% of subjects did not return for their 1-year follow-up FMD visit, which is consistent with the 30% to 43% 1-year dropout rates reported in other recent clinical trials of smoking cessation pharmacotherapy (28, 29) . Subjects who did not attend the follow-up visit were similar in age, sex, and race to those who did return, and they smoked a similar number of cigarettes/day at baseline. Although their baseline FMD was slightly lower, our findings were robust in many analyses, and it is unlikely that their inclusion would have changed our main finding: that smoking cessation improves endothelial function. Second-hand smoke exposure was not quantified in this study. The presence of second-hand smoke exposure may have led us to underestimate the effect of smoking cessation on FMD. Although significant efforts were made to recruit a racially diverse subject population, nonwhites constituted only about 16% of the study cohort. Differences in the associations between smoking and endothelial function by race may not have been detected. We did not administer nitroglycerin, so an effect of smoking cessation that is not endothelium mediated cannot be excluded. Finally, the long-term effect of smoking cessation on CVD risk was not evaluated; however, data collection for a 3-year analysis of carotid intima-media thickness is ongoing.
Conclusions
In this large, prospective study of current smokers, smoking intensity was independently associated with endothelial dysfunction. One year after smoking cessation, endothelial function improved significantly, despite weight gain. Improvements in endothelial function may mediate some of the reduced CVD risk observed after smoking cessation.
